MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2023.113393

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2023

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.

Schmid Peter, Lipatov Oleg, Im Seock-Ah, Goncalves Anthony, Muñoz-Couselo Eva, Lee Keun Seok, Tamura Kenji, Testa Laura, Witzel Isabell, Ohtani Shoichiro, Turner Nicholas, Zambelli Stefania, Harbeck Nadia, Andre Fabrice, Dent Rebecca, Mejia Jaime A, Zhou Xuan, Haiderali Amin, Nguyen Allison Martin, Cortes Javier, Winer Eric P

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In KEYNOTE-119 (ClinicalTrials.gov, NCT02555657), overall survival (primary end-point) was similar between pembrolizumab and chemotherapy in patients with previously treated metastatic triple-negative breast cancer (TNBC), although the pembrolizumab treatment effect increased with tumour PD-L1 expression. We report results of prespecified health-related quality of life (HRQoL) analyses from KEYNOTE-119.

METHODS

Eligible patients were randomised 1:1 to pembrolizumab 200 mg Q3W intravenously for up to 35 cycles or treatment of physician's choice per local/country guidelines. Prespecified exploratory end-points were the change from baseline in HRQoL (EORTC QLQ-C30, QLQ-BR23) and to characterise utilities (EQ-5D-3L). Time to deterioration (TTD) was the time from start of treatment to first onset of a ≥10-point worsening from baseline.

RESULTS

HRQoL analyses included 187 patients with tumour PD-L1 combined positive score (CPS) ≥10. Changes from baseline at 6 weeks (primary analysis time point) were directionally better with pembrolizumab versus chemotherapy for QLQ-C30 GHS/QoL (between-group difference in least-squares mean scores of 4.21 [95% CI, -1.38 to 9.80]), QLQ-C30 functional scales (physical, role, cognitive, social), QLQ-C30 symptom scales/items (fatigue, nausea/vomiting, dyspnoea, appetite loss), and QLQ-BR23 symptom scales/items (systemic therapy side-effects, upset by hair loss). Median TTD was directionally longer for pembrolizumab versus chemotherapy for QLQ-C30 QHS/QoL (4.3 versus 1.7 months), QLQ-C30 nausea/vomiting (7.7 versus 4.8 months), and QLQ-BR23 systemic therapy side-effects (6.1 versus 3.4 months). Minimal treatment differences were observed for other HRQoL end-points.

CONCLUSIONS

HRQoL results were consistent with clinical outcomes and appeared to be driven by results for patients with tumour PD-L1 CPS ≥10.

Для цитирования: Schmid Peter, Lipatov Oleg, Im Seock-Ah, Goncalves Anthony, Muñoz-Couselo Eva, Lee Keun Seok, Tamura Kenji, Testa Laura, Witzel Isabell, Ohtani Shoichiro, Turner Nicholas, Zambelli Stefania, Harbeck Nadia, Andre Fabrice, Dent Rebecca, Mejia Jaime A, Zhou Xuan, Haiderali Amin, Nguyen Allison Martin, Cortes Javier, Winer Eric P. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.. European journal of cancer (Oxford, England : 1990). 2023. DOI: 10.1016/j.ejca.2023.113393.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.